Papaverine-phentolamine and prostaglandin E1 versus papaverine-phentolamine alone for intracorporeal injection therapy: a clinical double-blind study.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 7637045.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A study was designed to compare intracorporeal injections of papaverine plus phentolamine (2-drug solution) and papaverine plus phentolamine and prostaglandin E1 (3-drug solution) for the treatment for impotence. A total of 20 impotent patients received intracorporeal injections of the 2-drug or 3-drug solution alternately during 2 sessions, and the quality and duration of erections were assessed. Of the patients 73% achieved a full erection with the 3-drug solution compared to 28% with the 2-drug solution. The average duration of erections was 57 minutes and 33.6 minutes, respectively. The complication rate was similar for the 2 treatments. Papaverine plus phentolamine and prostaglandin E1 is superior to papaverine plus phentolamine alone for the treatment of impotence.
Medical subject headings
- Alprostadil
- Erectile Dysfunction
- Papaverine
- Phentolamine